Moderate Psoriasis - Pipeline Review, H2 2014

Published: Aug, 2014 | Pages: 100 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Moderate Psoriasis - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Moderate Psoriasis - Pipeline Review, H2 2014', provides an overview of the Moderate Psoriasis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Moderate Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Moderate Psoriasis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Moderate Psoriasis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Moderate Psoriasis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Moderate Psoriasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Moderate Psoriasis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Moderate Psoriasis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Moderate Psoriasis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Moderate Psoriasis Overview 8
Therapeutics Development 9
Pipeline Products for Moderate Psoriasis - Overview 9
Pipeline Products for Moderate Psoriasis - Comparative Analysis 10
Moderate Psoriasis - Therapeutics under Development by Companies 11
Moderate Psoriasis - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Moderate Psoriasis - Products under Development by Companies 16
Moderate Psoriasis - Companies Involved in Therapeutics Development 17
Johnson & Johnson 17
Boehringer Ingelheim GmbH 18
Amgen Inc. 19
Eli Lilly and Company 20
Merck & Co., Inc. 21
AbGenomics International, Inc. 22
ApoPharma Inc. 23
Novartis AG 24
Pfizer Inc. 25
OPKO Health, Inc. 26
Idera Pharmaceuticals, Inc. 27
Almirall, S.A. 28
Syntrix Biosystems, Inc. 29
Vascular Biogenics Ltd. 30
Hy BioPharma Inc. 31
GlycoMar Limited 32
Convoy Therapeutics, Inc. 33
Moderate Psoriasis - Therapeutics Assessment 34
Assessment by Monotherapy Products 34
Assessment by Target 35
Assessment by Mechanism of Action 38
Assessment by Route of Administration 41
Assessment by Molecule Type 43
Drug Profiles 45
brodalumab - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
ixekizumab - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
secukinumab - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
tildrakizumab - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
LAS-41008 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
adalimumab biosimilar - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
baricitinib - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
AbGn-168H - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
VB-201 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
lunacalcipol - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
aminopterin sodium - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
HBP-347 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
orilotimod - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
BI-655066 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
IMO-8400 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
PF-04965842 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
MOL-4249 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
AVX-001 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
AMG-811 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
guselkumab - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
AKP-11 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
cyclosporine - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
GLY-2028 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Moderate Psoriasis - Recent Pipeline Updates 78
Moderate Psoriasis - Dormant Projects 95
Moderate Psoriasis - Discontinued Products 96
Moderate Psoriasis - Product Development Milestones 97
Featured News & Press Releases 97
Mar 28, 2012: Amgen Announces Publication Of Phase II Study Results Of Brodalumab For Treatment Of Psoriasis In New England Journal Of Medicine 97
Appendix 99
Methodology 99
Coverage 99
Secondary Research 99
Primary Research 99
Expert Panel Validation 99
Contact Us 100
Disclaimer 100

List of Tables
Number of Products under Development for Moderate Psoriasis, H2 2014 9
Number of Products under Development for Moderate Psoriasis - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 12
Comparative Analysis by Late Stage Development, H2 2014 13
Comparative Analysis by Clinical Stage Development, H2 2014 14
Comparative Analysis by Early Stage Development, H2 2014 15
Products under Development by Companies, H2 2014 16
Moderate Psoriasis - Pipeline by Johnson & Johnson, H2 2014 17
Moderate Psoriasis - Pipeline by Boehringer Ingelheim GmbH, H2 2014 18
Moderate Psoriasis - Pipeline by Amgen Inc., H2 2014 19
Moderate Psoriasis - Pipeline by Eli Lilly and Company, H2 2014 20
Moderate Psoriasis - Pipeline by Merck & Co., Inc., H2 2014 21
Moderate Psoriasis - Pipeline by AbGenomics International, Inc., H2 2014 22
Moderate Psoriasis - Pipeline by ApoPharma Inc., H2 2014 23
Moderate Psoriasis - Pipeline by Novartis AG, H2 2014 24
Moderate Psoriasis - Pipeline by Pfizer Inc., H2 2014 25
Moderate Psoriasis - Pipeline by OPKO Health, Inc., H2 2014 26
Moderate Psoriasis - Pipeline by Idera Pharmaceuticals, Inc., H2 2014 27
Moderate Psoriasis - Pipeline by Almirall, S.A., H2 2014 28
Moderate Psoriasis - Pipeline by Syntrix Biosystems, Inc., H2 2014 29
Moderate Psoriasis - Pipeline by Vascular Biogenics Ltd., H2 2014 30
Moderate Psoriasis - Pipeline by Hy BioPharma Inc., H2 2014 31
Moderate Psoriasis - Pipeline by GlycoMar Limited, H2 2014 32
Moderate Psoriasis - Pipeline by Convoy Therapeutics, Inc., H2 2014 33
Assessment by Monotherapy Products, H2 2014 34
Number of Products by Stage and Target, H2 2014 37
Number of Products by Stage and Mechanism of Action, H2 2014 40
Number of Products by Stage and Route of Administration, H2 2014 42
Number of Products by Stage and Molecule Type, H2 2014 44
Moderate Psoriasis Therapeutics - Recent Pipeline Updates, H2 2014 78
Moderate Psoriasis - Dormant Projects, H2 2014 95
Moderate Psoriasis - Discontinued Products, H2 2014 96